Netanyahu’s FMF-to-Zero Gambit: Hedge the Decouple Thesis

Source: https://x.com/i/status/2053628712860393584

Observation

In a filmed interview published by The Economist on January 9, 2026, Israeli Prime Minister Benjamin Netanyahu said he aims to taper the financial component of U.S. military assistance to Israel to zero over the next decade. Reuters and other outlets reported the remarks the next day. (archive.ph)

The current framework is the 2016 U.S.–Israel Memorandum of Understanding (MOU), which provides $38 billion over FY2019–FY2028 (about $3.8 billion per year), per the White House fact sheet and congressional research. (obamawhitehouse.archives.gov)

Netanyahu has paired the goal with a domestic plan reportedly allocating roughly NIS 350 billion (New Israeli shekels) over the next decade to expand Israel’s defense production, as covered by the Jerusalem Post on December 25, 2025. (jpost.com)

No directly comparable precedent surfaced in recent decades of an Israeli prime minister publicly proposing a decade‑long glide‑path to zero U.S. grant Foreign Military Financing (FMF); that novelty elevates this from routine MOU horse‑trading to an announced strategic aim. The stakes are material for foreign‑policy leverage, Israeli fiscal choices, and defense‑industry order books on both sides of the Atlantic.

Theme: can Israel credibly replace roughly $3.8bn/year in U.S. grant FMF with domestic financing and production within ten years—without preserving U.S. leverage? Tier‑3 readers care because the answer prices defense equities, reshapes export‑control risk for tech supply chains, and sets boundary conditions for corporate government‑affairs in the U.S., Israel, and third markets.

Call: for defense‑equity portfolio managers (PMs) and corporate government‑affairs (GA) leads with Israel exposure, hedge—not buy—the “FMF‑to‑zero” thesis: price in Israeli munitions scale‑up, but assume U.S. leverage via sustainment and export controls persists through the next MOU cycle. Avoid positioning for a clean decouple.

Geoeconomic Structure

The strongest pushback to a hedge posture is simple: if Israel stops taking $3.8bn/year in U.S. grants and self‑funds, money is fungible—U.S. leverage disappears. That reads cleanly at the budget line. It breaks at the supply line.

First, appropriations are only one lever. Sustainment and high‑end components for Israel’s core platforms are gated by the U.S. defense industrial base and the Foreign Military Sales (FMS) / Defense Security Cooperation Agency (DSCA) channels. F‑35 airframes and F135 engines (Lockheed Martin, Pratt & Whitney), F‑15/F‑16 sustainment (Boeing/Lockheed and U.S. Tier‑1 suppliers), and avionics/precision‑guided kits still run through U.S. export‑controlled pipelines. Even if grant funding wanes, spares, depot work, software loads, and overhaul cycles keep flowing through U.S. nodes. That is a chokepoint—procurement authority and logistics data pass through a U.S. gate that can shape cadence and conditions.

Second, Congress remains the gatekeeper. The 2016 MOU sets the topline, but Congress writes the checks, riders, and reporting requirements in the Department of State, Foreign Operations, and Related Programs (SFOPS) appropriations and wartime supplements. Committee language can reshape timing, tranches, or attach conditions—even if the strategic intent is to taper. In practical terms, this migrates leverage from a headline grant number to granular tools: reprogramming notifications, end‑use monitoring language, and sustainment eligibility constraints. The instrument changes; the control persists.

Third, the legal and regulatory architecture outlives the grant. U.S. export‑control authorities—International Traffic in Arms Regulations (ITAR) at State and Export Administration Regulations (EAR) at Commerce—and end‑use monitoring give Washington de facto vetoes over high‑end transfers and third‑party re‑exports. Unless Israel both finances and in‑sources the full stack—including energetics, complex microelectronics, and flight‑critical subsystems—it must import under licenses. That means leverage is increasingly technical and episodic (licenses, certifications, parts release), rather than purely budgetary. But it is leverage all the same.

Fourth, Israel’s domestic plan must clear a budget‑credibility bar. The reported NIS 350bn is an order‑of‑magnitude commitment to expand munitions and selective systems capacity via Elbit Systems, Rafael, and Israel Aerospace Industries. To translate from pledge to substitution, the Knesset and Treasury must enact multi‑year appropriations and the Israel Ministry of Defense (IMOD) must convert them into visible contract lots—multi‑year, multi‑billion‑shekel awards with delivery schedules. That can meaningfully replace U.S.‑sourced bulk munitions and some subsystems. It cannot, on a ten‑year window, fully replace sustainment and the highest‑end inputs that anchor Israel to U.S. supply chains without explicit technology‑access deals or license transitions—none publicly codified in binding texts today.

Fifth, timing asymmetry matters. The current MOU runs through FY2028; Netanyahu’s glide‑path targets a ten‑year arc from 2026. For leverage to collapse, the U.S. would have to allow a successor framework (or absence thereof) that dismantles conditionalities while simultaneously shifting sustainment and export‑control practice. Alternatively, Israel would have to fund and stand up domestic or non‑U.S. supply on a schedule tight enough to swap dependencies before the next major platform overhauls and block upgrades. Both are possible in pieces (domestic munitions, more local integration work), unlikely in whole within a decade absent a negotiated redesign. (obamawhitehouse.archives.gov)

Finally, commercial export dynamics cut both ways. As Israel scales domestic lines, exports can provide volume and foreign‑currency flows, partially subsidizing capacity. That supports the bull case for Israeli primes’ top lines. But export success can draw more—not less—regulatory scrutiny in the U.S. and Europe on technology transfer and end‑use, reinforcing the very levers that persist when grants fade.

Netting these layers, our read is straightforward: the FMF number can fall to zero and U.S. leverage can remain material. The chokepoints shift from the appropriations headline to sustainment supply, licensing, and programmatic governance. Israeli industry can and likely will grow munitions and selected systems capacity on NIS‑scale funding; that is investable. But a full strategic decouple within ten years—without compensating U.S. concessions—is not the base case.

Nine Star Ki Reading

We apply 九星気学 to the institutional actor at the fulcrum of the leverage question: the U.S. Congress, read as an authority figure. The lens tests whether the posture behind appropriations and licensing can still carry weight when grants recede.

Congress here maps to Six White Metal (Roppaku Kinsei, 六白金星), anchored in the image of a ministerial authority (大臣): hierarchical, formal, decisive, operating through rank and procedure rather than improvisation. That symbolism fits committee chairs, report language, and the choreography of appropriations that remains decisive in this analysis.

In the background, this actor is backed by a rule‑driven, boundary‑setting nature—authority that defaults to procedure, scrutiny, and institutional prerogative. What is showing now is that same authority forced to operate at North (Kankyū, 坎宮): a place of exposure and testing, where public scrutiny, media cycles, and partisan flux complicate smooth assertion of control. The verdict is that the background dominates the surface: things may look noisy or constrained today, but the underlying authority is still set to show through. For our reader, that means the procedural levers—appropriations riders, reporting requirements, licensing holds—are not a bluff.

In cycle terms, Congress sits at North and moves next toward Northeast. That shift points from a period of exposure and stress toward re‑established boundaries and a more settled, defensive stance. Translated into the policy arc: expect the leverage to harden into rule text and committee practice, not dissipate into rhetoric.

Recommendations

If you are a defense‑equity portfolio manager (PM) or a corporate government‑affairs (GA) lead with Israel/ITAR exposure, stay hedged. Treat Israeli munitions capacity expansion as a real revenue story; treat U.S. leverage through sustainment and export control as sticky. Keep overweight exposure to U.S. sustainment primes and program‑level service providers; re‑rate Israeli primes for domestic scale‑up, not for clean autonomy. For tech supply chains with Israeli nodes, do not price out regulatory frictions.

Watch these series to test the thesis over the next 6–24 months:

• U.S. FMF appropriations to Israel (SFOPS bill): any FY2029 committee report or bill text that reduces below the MOU baseline or codifies a glide‑path to zero within 12–24 months.
• Israel state budget: enactment of binding multi‑year appropriations committing ≥50% of the announced NIS 350bn within the first three years, within 6–12 months.
• IMOD domestic awards: cumulative multi‑year munitions/sustainment contracts to Elbit/Rafael/IAI exceeding $2bn within 6–18 months, visible in procurement notices and company filings.
• DSCA/FMS notifications to Congress (Israel): sustained totals ≥$2bn/year over the next 12 months indicate continued reliance on U.S. sustainment; a drop below that level would argue toward faster decouple.

Caveats and Open Questions

Three conditions would force us to revise the hedge toward a cleaner decouple positioning:

• Israeli Cabinet/Treasury/Knesset pass and publish binding multi‑year appropriations that legally commit a majority of the NIS 350bn plan (evidence: State Budget text and Knesset minutes). That would upgrade financing credibility and pull forward substitution timelines.
• The White House/State Department and the Israeli PMO jointly announce formal talks on a successor security framework that specify a U.S.‑approved glide‑path to zero and redesigned sustainment/tech‑access terms (evidence: joint statements, congressional briefings). That would re‑write the leverage architecture rather than letting it persist by default.
• Israeli primes sign and begin executing multi‑year domestic contracts that demonstrably substitute for prior U.S. purchases at scale—e.g., cumulative domestic awards reaching multiple billions of dollars within 24 months—paired with DSCA/FMS notifications to Israel falling below ~$2bn/year. That would reveal faster‑than‑expected in‑sourcing of what we assumed would stay U.S.‑gated.

Lead‑time question: how many months before we see either (i) a Knesset‑enacted multi‑year law committing ≥NIS 175bn of the defense plan, or (ii) DSCA/FMS notifications to Israel fall below $2bn/year—whichever comes first will decide whether to move from hedge to buying the decouple thesis.